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Cardiac transplantation is an established therapy for 
end-stage heart failure. Since the first human heart trans-
plantation in 1967, results have improved dramatically. 
One-year survival has increased to 85–90%. Within the 
first year, the early phase after transplantation is asso-
ciated with the highest risk of death [1]. The number of 
heart transplant procedures performed worldwide has 
remained relatively unchanged in recent years [2]. But 
the growing number of patients wait-listed each year 
2 creates an ever-expanding demand for transplantati-
on [3].
Although mortality rates on the waiting list have im-
proved due to improved ventricular assist devices and 
rhythm correction techniques, it remains imperative to 
maximize use of all potential donor hearts. However, 
expansion of the donor pool must be balanced against 
the risk of adversely affecting outcomes [4].
The recipient now presents with multiple complexi-
ties, and there is increasing acceptance to tolerate these 
conditions, a reflection of the changing epidemiology 
of transplantation. In heart transplantation, age has in-
creased significantly during the past 2 decades, with an 
ever-increasing proportion of recipients older than 60 
years (24% of all recipients in 2006 up to 29% in 2016). 
Similarly, patients with complex congenital heart disease 
(CHD) and those with underlying chronic infections and 
conditions, such as cardiac amyloidosis, are now accep-
table candidates for transplantation [5].
Not surprisingly, the burden of recipient comorbi-
dities has increased in parallel, with increases in reci-
pient weight, prior smoking history, hypertension, and 
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diabetes. Indeed, the prevalence of recipient diabetes 
mellitus, which was initially considered a contraindica-
tion to transplantation, has increased from 15% in the 
1992 to 2003 era to 27% in the most recent era of 2009 
to June 2017.
Adding to the complexity of finding an appropriate 
donor match and post-operative immunosuppression is 
the observation that the proportion of sensitized can-
didates (defined as panel reactive antibody >10%) has 
increased from 8% 15 to 20 years ago to >20% today. 
This partly reflects the increasing use of mechanical cir-
culatory support as a bridge to transplantation. Currently, 
more than 50% of patients are bridged with one or more 
forms of mechanical support, including percutaneous 
and durable ventricular assist devices (VADs), total ar-
tificial heart, and extracorporeal membrane oxygenation 
(ECMO), such that conducting heart transplantation in a 
patient without a previous sternotomy has become quite 
unusual [6].
Advances in reparative surgery for CHD have resul-
ted in a higher number of CHD patients who achieve 
better quality of life and longer survival, yet many pro-
gress to requiring transplantation (e.g., «failing» Fontan 
physiology). Despite the increased risk of peri-transplant 
complications and early post-transplant mortality, CHD 
transplant recipients tend to have a very good prognosis 
in the long-term. These patients, who often have con-
comitant liver disease, may be evaluated for combined 
heart-liver transplantation.
The decision to perform such combined organ trans-
plant procedures in patients with advanced CHD is 
never straightforward, and the indications, operative 
techniques, and post-operative care strategies are still 
being evaluated, debated, and revised. Progress in can-
cer therapy provides lasting remission to many patients, 
yet the cardiotoxicity of chemotherapeutic agents may 
lead to the need for heart transplantation, with its spe-
cific challenges for perioperative and long-term care. 
Increasingly, patients with prior cancer and a history 
of chest wall radiation present a unique complex group 
that requires better study for suitability [5]. The standard 
criteria for acceptability of a donor heart which were 
published in the mid 1990s stipulated a donor age <50 
years, no segmental abnormalities or global hypokinesis, 
left ventricular ejection fraction (LVEF) >50%, normal 
valvular structure, normal ECG or only minor ST-T wave 
abnormalities, a short ischemic time (<4 hours), dopami-
ne dose <15 µg/kg/min, donor-to-recipient weight ratio 
0.7 ± 1.5, and no donor infection including hepatitis B 
virus (HBV), hepatitis C virus (HCV) and HIV infection 
[7]. These strict criteria, however, severely restricted 
acceptance of potential donor hearts. A series of groups 
published evidence showing that the criteria could be 
expanded without compromising outcomes, leading to 
progressive acceptance of hearts from donors with longer 
ischemic times, wider 5 size mismatch, left ventricular 
hypertrophy, significant coronary artery disease, HCV 
or HBV infection and non-heart-beating donors [8–10].
The continued divergence between the rising number 
of transplant candidates added to the transplant wai-
ting list and the number of suitable organ donors has 
increased pressure on clinicians to maximize the use of 
available thoracic organs for transplantation. Donor age 
at acceptance is increasing, as are underlying comorbi-
dities. Median donor age in 2016 was 32 years in adult 
heart and 38 years in adult lung transplantation. Trans-
plantation of heart and lung allografts from well selected 
donors aged >60 years is no longer uncommon. A recent 
analysis of data from the Spanish Heart Transplantation 
Registry was cautiously reassuring, demonstrating no 
survival disadvantage in recipients of donor hearts aged 
more than 50 years. However, after multivariate adjust-
ment, recipients of these older hearts did have a higher 
incidence of cardiac allograft vasculopathy at 5 years 
after transplant [11]. Based on the International Society 
for Heart and Lung Transplantation (ISHLT) registry, the 
rate of death from graft failure early after transplantation 
is 3–4%. However, more and more data are available 
that shows significant differences of the cardiac donor 
population and its management in the USA and Europe. 
In Europe, donors are significantly older and are treated 
with a different inotropic regime than in the USA. Ac-
cording to the ISHLT registry, the rate of donors who are 
>50 years of age has been constant at 10% over the last 
years. This is in sharp contrast to the donor population in 
this cohort, which comprises 50% of donor hearts aged 
50 and above. Norepinephrine support in doses >0.3 mg 
kg1 min1 was used in >80% of donors. According to 
the definitions of marginal donors, this center has been 
using marginal donors in many cases. Over the last 10 
years, using so-called «marginal donors» has become the 
routine in Europe’s cardiac transplantation programs. If 
centers would only use standard donor hearts, they would 
have a significant reduction in transplant numbers [12].
Much interest has recently been given to donor hearts 
with left ventricular dysfunction, which is often caused 
by transient neurogenic injury. There is now convincing 
evidence that donor hearts with left ventricular dysfunc-
tion often improve during donor management and yield 
acceptable recipient outcomes after transplantation. In 
fact, even donor hearts that continue to have reduced 
function at the time of organ procurement may be safely 
transplanted [13, 14].
Deaths related to drug intoxication are on the rise, 
with opioid abuse reaching epidemic proportions in the 
United States. Consequently, drug overdose is an incre-
asingly common donor cause of death. Illicit drug use 
is more frequent even in potential donors with other 
mechanisms of death – 12% of all donors have a history 
of cocaine use, 44% of whom are current users. Many 
potential donors dying of drug overdose are also hepa-
titis C virus positive. This pool of donors represents an 
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opportunity to increase thoracic transplant rates, given 
the recent availability of highly effective direct-acting 
antiviral therapy for hepatitis C virus [15–17].
Increasing use of organs from donation after circula-
tory death (DCD) also provides promise for expansion of 
the donor pool for thoracic transplantation. Although this 
approach adds complexity to the transplant process, DCD 
heart transplant has now been shown to have long-term 
outcomes similar to lung transplant with allograft [18].
Yet, clinical implementation of DCD heart transplan-
tation remains relatively slow, partly due to ethical and 
regulatory considerations and partly to the concern for 
high susceptibility of the myocardium to ischemia. Ex 
vivo organ perfusion techniques, recently tested for cli-
nical application in organ transplantation, may enhance 
the feasibility of DCD organ donation. This has also 
ushered in the era of reconditioning of donated organs 
not immediately suitable for transplantation, especially 
for lung transplantation [19].
Recent changes in treatment of advanced heart and 
lung disease and changes in donor demographics have 
put a strain on existing organ allocation systems. Many 
countries have re-examined how well their allocation 
algorithms ensure that organ allocation is equitable. The 
implementation of the Lung Allocation Score in the Uni-
ted States, Germany, and the Netherlands was intended to 
strengthen utilitarian features of the allocation algorithm 
by considering the risk of death on the waiting list and 
in the first year after transplant [20].
In contrast, cardiac allocation is still mainly «urgen-
cy» driven, based mostly on the assessment of mortality 
risk on the waiting list. The United States heart allocation 
policy will soon undergo a major change, implementing 
new urgency tiers and expanding regional organ sharing 
[21]. In Europe, efforts are underway to create a heart 
allocation score via integration of information from exis-
ting heart failure survival scores, post-transplant out-
come scores, and public registries [22]. Decision-making 
about acceptance or non acceptance of a «marginal» 
donor heart, however, is complex. Additionally, the risk 
profile of the potential recipient must also be taken into 
account, for example when the donor is aged over 55 
years or has a low ejection fraction. Combined donor and 
recipient risk profiling can help to predict post-transplant 
survival rates and is useful in general terms but when 
faced with a specific donor an individualized assessment 
of that particular donor and heart – and the candidate 
recipient – is required. This decision-making progress is 
largely unsupported by rigorous evidence and depends to 
a large extent on the experience of the clinician. Refining 
this process is difficult because data on the outcomes for 
donor hearts transplanted elsewhere after non-acceptance 
are not readily available [23].
What is remarkable in the context of what could be 
seen as the «perfect storm» at the intersection of a higher 
risk donor, a more complicated transplant recipient, and 
the ever changing regulatory environment, is that the 
volume of thoracic transplantation continues to increa-
se and that contemporary survival after heart, lung and 
heart-lung transplant continues to improve. Perhaps one 
of the greatest drivers of this change is the irrepressible 
urge to continue to explore the limits of what is possi-
ble, and our collective contributors to the International 
Society of Heart and Lung Transplantation International 
Thoracic Organ Transplant Registry deserve gratitude for 
pushing the boundaries for patients worldwide.
The authors declare no conflict of interest.
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